NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

Core Insights - NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines [2] - The company will participate in the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, with a presentation scheduled for March 11 at 8:00 AM ET [1] Company Overview - NovaBridge combines business development expertise with agile translational clinical development to advance breakthrough assets [2] - The company aims to bridge science, strategy, and execution to facilitate the rapid progression of transformative therapies from discovery to patients [2] Product Pipeline - The leading product in NovaBridge's pipeline is givastomig, a bispecific antibody targeting Claudin 18.2, currently in a global Phase 2 study for gastric cancer [3][4] - VIS-101, another key product, targets VEGF-A and ANG-2 for treating wet age-related macular degeneration and diabetic macular edema, and is completing a Phase 2a study [5] Collaborations and Rights - NovaBridge collaborates with ABL Bio for the development of ragistomig, a bispecific antibody for solid tumors [4] - The company holds worldwide rights outside of China for uliledlimab, an anti-CD73 antibody targeting immunosuppression in cancer [4]